Brazil · Delayed Price · Currency is BRL Regeneron Pharmaceuticals Company Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy.
Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
| Country | United States |
| Founded | 1988 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15,106 |
| CEO | Leonard Schleifer |
Contact Details
Address: 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 United States | |
| Phone | 914 847 7000 |
| Website | regeneron.com |
Stock Details
| Ticker Symbol | REGN34 |
| Exchange | Brazil Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Co-Chairman |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer and Co-Chairman |
| Christopher R. Fenimore CPA | Executive Vice President of Finance and Chief Financial Officer |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research and Co-Chief Scientific Officer |
| Daniel P. Van Plew | Executive Vice President and GM of Industrial Operations and Product Supply |
| Rajesh Ahuja | Senior Vice President of Quality Assurance and Operations |
| Bob McCowan | Senior Vice President of IT and Chief Information Officer |
| Ryan Crowe | Senior Vice President of Investor Relations and Strategic Analysis |
| Joseph J. LaRosa J.D. | Executive Vice President, General Counsel and Secretary |
| Melissa Lozner | Senior Vice President and Chief Compliance Officer |